Application of combined dynamic detection of serum tumor markers in the diagnosis and treatment of breast cancer

  Objective  To explore the clinical value of differently and dynamically combined detection of serum carbohydrate antigen 153(CA153), serum carbohydrate antigen 125 (CA125) and osteopontin (OPN) for the diagnosis and monitoring of breast cancer.

  Methods  A total of 98 patients with breast cancer, 50 patients with benign breast lesions and 50 healthy donors were as breast cancer group, benign control group and normal control group. The levels of serum CA153, CA125 in three groups were detected through electrochemiluminescence, and the level of OPN was measured by enzyme-linked immunosorbent. The correlations between the levels of CA153, CA125, OPN and benign, malignant breast diseases were analyzed.

  Results  ① The levels of serum CA153, CA125 and OPN in the breast cancer group were obviously higher than the benign group and healthy control group (P < 0.01). There was no significant difference between the benign control group and the normal control group (P>0.05). ② The serum CA153, CA125 and OPN levels in patients with breast cancer were not correlated with age and tumor location (P>0.05), while were significantly correlated with the tumor size, clinical staging, metastasis, recurrence and post-treatment. The levels of serum CA153, CA125 and OPN in the breast cancer patients with high stagings (Ⅲ, Ⅳ) were significantly higher than those with low stagings (Ⅰ, Ⅱ) (P < 0.01), and there were significant differences between patients with lymph node metastasis and those with non-metastasis, between recurrence patients and those without (P < 0.01). Furthermore, the levels of serum CA153, CA125 and OPN after treatment were obviously decreased compared with treatment before (P < 0.01). ③ The sensitivity and accuracy of combined detection of serum CA153, CA125 and OPN were significantly improved compared with detection alone or partial combined detection.

  Conclusion  The diagnostic detection of serum CA153, CA125 and OPN in combination for breast cancer has significantly higher detection rate, and decreased misdiagnosis and missed diagnosis, which is helpful for early clinical discovery and intervention. Meanwhile, the dynamically combined detection can monitor the tumor metastasis and recurrence, assess the prognosis.